Key Takeaways
- Century Therapeutics has appointed Dr. Han Lee and Dr. Martin Murphy to its Board of Directors.
- Dr. Lee will join the Audit and Compensation Committees, while Dr. Murphy will serve on the Compensation and Nominating Committees.
- The company aims to advance its iPSC-derived therapies, including CNTY-813 for type 1 diabetes, to improve patient access to treatments.
New Board Appointments Enhance Century Therapeutics’ Strategic Focus
Century Therapeutics, a biotechnology company listed on NASDAQ (IPSC) and focused on developing induced pluripotent stem cell (iPSC)-derived therapies, has recently appointed Dr. Han Lee and Dr. Martin Murphy to its Board of Directors. These appointments come during a crucial phase for the company as it seeks to bring its innovative therapies, particularly CNTY-813, an investigational treatment for type 1 diabetes, closer to patients.
Dr. Lee, who holds a Ph.D. and an M.B.A. from Yale University, has substantial experience in financial management and corporate development. He previously served as President and Chief Financial Officer of ImmPACT Bio, which was acquired in 2024. Dr. Murphy is also well-versed in the life sciences sector, having held directorships at various organizations and co-founding Syncona Limited. His academic credentials include a Ph.D. from the University of Cambridge and an M.A. in biochemistry from the University of Oxford.
CEO Brent Pfeiffenberger expressed confidence in the new board members, highlighting their expertise in financial and strategic oversight. Their experience is anticipated to facilitate the company’s goal of expediting its lead pipeline candidates into clinical trials and generating substantial value for both patients and stakeholders.
Century Therapeutics is dedicated to creating accessible cell therapies through its proprietary Allo-Evasion™ technology, aimed at treating autoimmune diseases and cancers. The company’s focus on developing off-the-shelf solutions is expected to improve patient access and provide competitive advantages over existing therapies.
As Century Therapeutics progresses with its ambitious plans, it acknowledges the inherent risks associated with clinical development, including regulatory approvals and market opportunities. Nonetheless, the company remains optimistic about leveraging its newly strengthened board to advance its mission to enhance care for patients with critical health challenges.
For more information about Century Therapeutics, please visit their website.
The content above is a summary. For more details, see the source article.